Targeting leukaemia stem cells through inhibition of telomerase [ 2016 - 2018 ]

Research Grant

Researchers: A/Pr Steven Lane (Principal investigator)

Brief description Acute myeloid leukaemia (AML) is a type of very aggressive blood cancer that kills up to 1000 Australians every year. We use chemotherapy to treat AML, however, most patients are not cured by chemotherapy alone and the disease eventually comes back (relapses). We are looking at a new type of treatment for patients with AML that targets the genetic material (DNA) within the leukaemia cells. Our work has shown that this new type of treatment may prevent relapse after chemotherapy.

Funding Amount $AUD 670,116.82

Funding Scheme Project Grants

Notes Standard Project Grant